Massive data dive reveals sex gaps in popular Heart-Kidney drugs
NCT ID NCT07188545
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looks at health records from over 23 million people to see if common heart and kidney drugs (GLP-1 agonists and SGLT2 inhibitors) affect men and women differently. Researchers want to understand if these drugs work equally well for both sexes in preventing heart attacks, strokes, and kidney problems. The goal is to improve treatment for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR KIDNEY METABOLIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University
Columbus, Ohio, 43202, United States
Conditions
Explore the condition pages connected to this study.